Latest News and Press Releases

U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution,...

Statistically significant efficacy in biomarker subgroup analyses was observed: 78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of...

Activated b-catenin or loss of its negative regulator adenomatous polyposis coli (APC) is a potential biomarker for NT219 in the treatment of colorectal cancerNT219’s mechanism of action informs how...

Findings show combination therapy of NT219 and 5-flourouracil (5-FU) inhibits colorectal cancer brain metastasis through the IRS2 pathway IRS2, a novel target of NT219, is identified as a driver of...

REHOVOT, Israel, April 01, 2025 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...

Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers CM24 is well positioned for personalized treatment, with...

NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd....

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab...

Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing tumor-specific immunity against multiple cancer...